Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» eczema
eczema
Incyte Says FDA Grants Priority Review For Eczema Cream
Incyte Says FDA Grants Priority Review For Eczema Cream
Yahoo/SmarterAnalyst
Incyte
eczema
FDA
priority review
ruxolitinib
Flag link:
Regeneron has a winner in Dupixent and big sales hopes. So why are so few patients taking it?
Regeneron has a winner in Dupixent and big sales hopes. So why are so few patients taking it?
Endpoints
Dupixent
Regeneron
Sanofi
eczema
Flag link:
Sanofi inks $1.1B Kymab buyout to bag midphase eczema drug
Sanofi inks $1.1B Kymab buyout to bag midphase eczema drug
Fierce Biotech
Sanofi
Kymab
M&A
atopic dermatitis
eczema
monoclonal antibodies
Flag link:
Novartis dumps Ziarco eczema drug, taking $485M hit
Novartis dumps Ziarco eczema drug, taking $485M hit
Fierce Biotech
Novartis
eczema
Ziarco
M&A
ZPL389
Flag link:
LEO eyeing 2021 US launch for eczema drug tralokinumab
LEO eyeing 2021 US launch for eczema drug tralokinumab
Pharmaforum
LEO Pharma
eczema
tralokinumab
Sanofi
Dupixent
Flag link:
AAD 2020 – Leo’s eczema wildcard proves tame
AAD 2020 – Leo’s eczema wildcard proves tame
EP Vantage
LEO Pharma
Sanofi
Regeneron
eczema
atopic dermatitis
AAD
tralokinumab
Flag link:
Pfizer's JAK abrocitinib comes through in teen eczema test
Pfizer's JAK abrocitinib comes through in teen eczema test
Fierce Biotech
Pfizer
abrocitinib
eczema
atopic dermatitis
clinical trials
Flag link:
New safety data expose potential weakness as Pfizer's abrocitinib takes on Dupixent in eczema
New safety data expose potential weakness as Pfizer's abrocitinib takes on Dupixent in eczema
Endpoints
Pfizer
abrocitinib
Dupixent
clinical trials
eczema
Flag link:
LEO Pharma mounts another challenge to the eczema giants, betting $40M cash on a drug from China
LEO Pharma mounts another challenge to the eczema giants, betting $40M cash on a drug from China
Endpoints
LEO Pharma
eczema
asthma
clinical trials
FB825
China
Flag link:
Eli Lilly and Incyte Record Another Positive Clinical Trial for Olumiant Works in Eczema
Eli Lilly and Incyte Record Another Positive Clinical Trial for Olumiant Works in Eczema
Motley Fool
Eli Lilly
Incyte
olumiant
eczema
clinical trials
atopic dermatitis
Flag link:
Pfizer Edges Higher After Positive Trials for Moderate-to-Severe Eczema Drug
Pfizer Edges Higher After Positive Trials for Moderate-to-Severe Eczema Drug
TheStreet.com
Pfizer
clinical trials
eczema
abrocitinib
Flag link:
Dermira shares double on positive eczema data
Dermira shares double on positive eczema data
Biopharma Dive
Dermira
lebrikizumab
clinical trials
eczema
Flag link:
Upcoming events – Ascendis and Lilly hope for growth with pivotal data
Upcoming events – Ascendis and Lilly hope for growth with pivotal data
EP Vantage
Ascendis
clinical trials
pediatric growth hormone deficiency
TransCon hGH
Eli Lilly
olumiant
eczema
Flag link:
Hoth Therapeutics seeks IPO cash to battle eczema
Hoth Therapeutics seeks IPO cash to battle eczema
Fierce Biotech
Hoth Therapeutics
IPOs
NASDAQ
eczema
Flag link:
Sanofi unveils eczema drug data, as regulators mull label expansion
Sanofi unveils eczema drug data, as regulators mull label expansion
Pharmaforum
Sanofi
Dupixent
dupilumab
eczema
atopic dermatitis
Flag link:
Zai Lab bombs Phase IIa trial in atopic dermatitis, junks the program to shift resources to the pipeline
Zai Lab bombs Phase IIa trial in atopic dermatitis, junks the program to shift resources to the pipeline
Endpoints
Zai Lab
ZL-3101
Fugan
eczema
Shanghai
clinical trials
Flag link:
2 Biotech Stocks Near All-Time Highs: Can They Keep Climbing?
2 Biotech Stocks Near All-Time Highs: Can They Keep Climbing?
Motley Fool
biotech
BeiGene
China
Celgene
AnaptysBio
ANB020
eczema
Flag link:
Sanofi and Regeneron's Dupixent launch is about to get a cash infusion
Sanofi and Regeneron's Dupixent launch is about to get a cash infusion
Fierce Pharma
Sanofi
Regeneron
Dupixent
drug launches
eczema
JPMHC 2018
Flag link:
Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status
Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status
Fierce Pharma
Pfizer
Eucrisa
DTC
eczema
Dupixent
Sanofi
Regeneron
Flag link:
Dermira Commits $135M for Global Rights to Roche Eczema Drug
Dermira Commits $135M for Global Rights to Roche Eczema Drug
Xconomy
Demira
Roche
eczema
lebrikizumab
Flag link:
Pages
1
2
3
next ›
last »